Amendments to the claims:

This listing of the claims will replace all prior versions, and listings of claims in the application.

Listing of Claims:

1. (Currently Amended) A process for separating fibronectin from a plasma fraction~~, characterized in that~~ comprising the steps of:

(i) adjusting the pH value of the plasma fraction ~~is adjusted~~ to below pH 5.4 so as to form a precipitate, the ionic strength of the plasma fraction being below 500 mM,

(ii) separating the precipitate formed ~~is separated~~.

2. (Currently Amended) A process for the production of a composition containing a coagulation factor, comprising the steps of:

(i) adjusting the pH of a plasma fraction to below pH 5.4 so as to form a precipitate, the ionic strength of the plasma fraction being below 500 mM, and

(ii) separating the precipitate formed.

3. (Currently Amended) The process according to claim 1 ~~or 2~~, characterized in that the pH of the plasma fraction is adjusted to a value between pH 4.7 and pH 5.3.

4. (Currently Amended) The process according to ~~any of claims 1 to 3~~claim 1, characterized in that the ionic strength of the plasma fraction is below 300 mM.

5. (Currently Amended) The process according ~~to any of claims 1 to 3~~claim 1, characterized in that the ionic strength of the plasma fraction is below 200 mM.

6. (Currently Amended) The process according to ~~any of claims 1 to 5~~claim 1, characterized in that after adjusting the pH value in step (i), the plasma fraction is stirred for at least 10 minutes.

7. (Currently Amended) The process according to ~~any of claims 1 to 6~~claim 1, characterized in that the majority of the fibronectin precipitate is separated by means of ~~the~~ an agitator blade of a stirrer.

8. (Currently Amended) The process according to ~~any of claims 1 to 7~~claim 1, characterized in that before step (i), the fibronectin concentration in the plasma fraction is at least 0.1 g per liter.

9. (Currently Amended) The process according to ~~any of claims 1 to 8~~claim 1, characterized in that the concentration of NaCl or KCl in the plasma fraction is 100 – 200 mM.

10. (Currently Amended) The process according to ~~any of claims 1 to 9~~claim 1, characterized in that the ~~starting solution~~plasma fraction initially contains glycine at a concentration below 500 mM.

11. (Currently Amended) The process according to ~~any of claims 1 to 10~~claim 1, characterized in that the ~~starting solution~~plasma fraction initially contains glycine at a concentration below 200 mM.

12. (Currently Amended) The process according to ~~any of claims 1 to 11~~claim 1, characterized in that the ~~starting solution~~plasma fraction initially contains glycine at a concentration of 50 to 200 mM.

13. (Currently Amended) The process according to ~~any of claims 1 to 12~~claim 1, characterized in that the ~~starting solution~~ plasma fraction initially contains glycine at a concentration of 100 to 150 mM.

14. (Currently Amended) The process according to ~~any of claims 1 to 13~~claim 1, characterized in that the plasma fraction is dissolved cryoprecipitate.

15. (Original) The process according to claim 14, characterized in that the dissolved cryoprecipitate is previously purified by aluminum hydroxide treatment, solvent/detergent treatment and anion exchange chromatography.

16. (Currently Amended) The process according to ~~any of claims 1 to 15~~claim 1, characterized in that after step (ii), at least one coagulation factor is purified.

17. (Original) The process according to claim 16, characterized in that the coagulation factor is von Willebrand factor.

18. (Currently Amended) A c~~C~~oagulation factor~~, obtainable~~ obtained by a process according to claim 16 ~~or 17~~.